Sentiment for Aerie Pharmaceuticals Inc (NASDAQ:AERI)
Aerie Pharmaceuticals Inc (NASDAQ:AERI) institutional sentiment decreased to 1.1 in Q4 2018. Its down -0.47, from 1.57 in 2018Q3. The ratio is negative, as 77 investment professionals increased and opened new positions, while 70 sold and decreased holdings in Aerie Pharmaceuticals Inc. The investment professionals in our partner’s database now have: 45.76 million shares, up from 43.94 million shares in 2018Q3. Also, the number of investment professionals holding Aerie Pharmaceuticals Inc in their top 10 positions decreased from 4 to 3 for a decrease of 1. Sold All: 25 Reduced: 45 Increased: 55 New Position: 22.
Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. The company has market cap of $2.16 billion. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension. It currently has negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.
The stock decreased 1.12% or $0.53 during the last trading session, reaching $46.98. About 447,334 shares traded. Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has declined 7.21% since March 17, 2018 and is downtrending. It has underperformed by 11.58% the S&P500.
Analysts await Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to report earnings on May, 14. They expect $-0.83 EPS, up 20.95 % or $0.22 from last year’s $-1.05 per share. After $-0.92 actual EPS reported by Aerie Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -9.78 % EPS growth.
Foresite Capital Management Ii Llc holds 32% of its portfolio in Aerie Pharmaceuticals, Inc. for 1.67 million shares. Sectoral Asset Management Inc owns 1.13 million shares or 5.56% of their US portfolio. Moreover, Healthcor Management L.P. has 2.82% invested in the company for 1.31 million shares. The California-based Dafna Capital Management Llc has invested 2.55% in the stock. Daruma Capital Management Llc, a New York-based fund reported 465,981 shares.
Since January 1, 0001, it had 1 buy, and 5 insider sales for $5.93 million activity.
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage
Ratings analysis reveals 100% of Aerie Pharmaceuticals’s analysts are positive. Out of 7 Wall Street analysts rating Aerie Pharmaceuticals, 7 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $64 while the high is $105. The stock’s average target of $78.86 is 67.86% above today’s ($46.98) share price. AERI was included in 15 notes of analysts from November 13, 2018. JMP Securities maintained the shares of AERI in report on Tuesday, February 26 with “Buy” rating. Cantor Fitzgerald maintained it with “Buy” rating and $85 target in Tuesday, February 26 report. The rating was maintained by Mizuho on Friday, March 1 with “Buy”. The company was maintained on Wednesday, March 13 by H.C. Wainwright. The firm has “Buy” rating by Oppenheimer given on Tuesday, March 12. H.C. Wainwright maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) on Tuesday, February 26 with “Buy” rating. The company was maintained on Tuesday, February 26 by Cowen & Co. The rating was maintained by Canaccord Genuity with “Buy” on Monday, March 4. On Thursday, February 21 the stock rating was maintained by Oppenheimer with “Buy”. Mizuho maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rating on Friday, February 22. Mizuho has “Buy” rating and $77 target.
More notable recent Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news were published by: Benzinga.com which released: “68 Biggest Movers From Yesterday – Benzinga” on March 14, 2019, also Nasdaq.com with their article: “ETF Preview: ETFs, Futures Edge Higher as Wall Street Digests Durable Goods, PPI Data – Nasdaq” published on March 13, 2019, Benzinga.com published: “Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates – Benzinga” on March 04, 2019. More interesting news about Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) were released by: Businesswire.com and their article: “Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results, Provides 2019 Cash Burn Guidance and Business Update – Business Wire” published on February 25, 2019 as well as Benzinga.com‘s news article titled: “Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings, IPOs (March 10-16) – Benzinga” with publication date: March 10, 2019.